...
机译:在复发/难治性B细胞急性淋巴细胞白血病中的新药测序:Blinatumomab和Inotuzumab ozogamicin可以具有相当的疗效,作为第一或第二新试剂治疗复发/难治性急性淋巴细胞白血病
Med Coll Wisconsin Div Hematol &
Oncol 9200 W Wisconsin Ave Milwaukee WI 53226 USA;
Med Coll Wisconsin Div Hematol &
Oncol 9200 W Wisconsin Ave Milwaukee WI 53226 USA;
Northwestern Hosp Robert H Lurie Comprehens Canc Ctr Chicago IL USA;
Stanford Univ Ctr Canc Stanford CA 94305 USA;
Northwestern Hosp Robert H Lurie Comprehens Canc Ctr Chicago IL USA;
Yale Sch Med Dept Internal Med Sect Hematol New Haven CT USA;
Stanford Univ Ctr Canc Stanford CA 94305 USA;
Stanford Univ Ctr Canc Stanford CA 94305 USA;
Med Coll Wisconsin Div Hematol &
Oncol 9200 W Wisconsin Ave Milwaukee WI 53226 USA;
Karmanos Canc Inst Detroit MI USA;
Karmanos Canc Inst Detroit MI USA;
Mayo Clin Div Hematol Rochester MN USA;
Yale Sch Med Dept Internal Med Sect Hematol New Haven CT USA;
Univ Chicago Dept Med Sect Hematol Oncol 5841 S Maryland Ave Chicago IL 60637 USA;
Univ Chicago Dept Med Sect Hematol Oncol 5841 S Maryland Ave Chicago IL 60637 USA;
Univ Chicago Dept Med Sect Hematol Oncol 5841 S Maryland Ave Chicago IL 60637 USA;
City Hope Natl Med Ctr Dept Hematol &
Hematopoiet Cell Transplantat Duarte CA USA;
City Hope Natl Med Ctr Dept Hematol &
Hematopoiet Cell Transplantat Duarte CA USA;
Cleveland Clin Taussig Canc Inst Dept Hematol &
Med Oncol Cleveland OH 44106 USA;
Univ Wisconsin Carbone Canc Ctr Madison WI USA;
Mayo Clin Div Hematol Rochester MN USA;
Dana Farber Canc Inst Dept Med Oncol Boston MA 02115 USA;
Cleveland Clin Taussig Canc Inst Dept Hematol &
Med Oncol Cleveland OH 44106 USA;
Med Coll Wisconsin Div Hematol &
Oncol 9200 W Wisconsin Ave Milwaukee WI 53226 USA;
allogeneic hematopoietic stem cell transplantation (alloamp; 8208; HCT); blinatumomab; inotuzumab ozogamicin; relapsed; refractory (RR) acute lymphoblastic leukemia (ALL);
机译:减少强度化疗加入inotuzumab ozogamicin,有或没有顺序的Blinatumomab,作为第一次复发/难治性B细胞急性淋巴细胞白血病的第一次挽救治疗
机译:Blinatumomab与在美国复发或难治性B细胞前体急性淋巴细胞白血病成年患者中的Blinatumomab对ozuzumab ozogamicin的成本有效性
机译:使用inotuzumab ozogamicin和迷你超cvd的组合使用或没有Blinatumomab复发/难以满足染色体阴性急性淋巴细胞白血病的长期随访
机译:利用人工神经网络优化急性淋巴细胞白血病和急性髓性白血病样品的分类
机译:复发性急性淋巴细胞白血病中NT5C2突变的机制和治疗靶点
机译:Inotuzumab Ozogamicin在复发或难治性B细胞急性淋巴细胞白血病中的作用
机译:对Blinatumomab和Inotuzumab ozogamicin治疗患者的反应特征,在真正的临床实践中复发/难治性B细胞急性淋巴细胞白血病
机译:接受骨髓移植治疗急性白血病患者中枢神经系统复发和白质脑病的风险